

# **PRODUCT DATA SHEET**

# Product: TNF-R2, human recombinant

# Cat. No: TN-004 (50 µg)

## Background:

**TNF-Receptors** (TNF-R) are implicated in inflammatory processes and are the prototype members of the TNF receptor family. There are two distinct TNF-R, i.e. TNF-R1 and TNF-R2, that interact with the ligand TNF- $\alpha$ . Whereas both receptors activate NF-κB and JNK. TNF-R1 also signals cell death. Activated TNF-R1 contains a death domain in its cytoplasmic region that recruits the adaptor proteins TRADD, RIP, FADD, and TRAF2. TNF-R2 recruits TRAF proteins. Whereas membrane-bound and processed, soluble TNF- $\alpha$  bind to TNF-R1, only the membrane-bound form appears to interact with TNF-R2.

Molecular Weight: 80 kDa (chimeric protein)

### Specificity:

Highly specific for the detection of membranebound TNF- $\alpha$ .

#### Species Reactivity:

Human, other species not tested.

#### Source:

Recombinant human TNF-R2:Fc. The recombinant protein is produced in HEK 293 cells. The extracellular domain of human TNF-R2 (aa 1-257) is fused to the Fc portion of human lgG1.

# Format:

Lyophilized powder. Contains PBS. Purity >95% as determined by SDS-PAGE.

#### **Preparation:**

Prepare a sterile stock solution of rhTNF-R2:Fc (1 mg/ml in PBS) by dissolving the entire preparation in 50  $\mu$ l sterile H<sub>2</sub>O. Further dilutions should be made with medium containing 5% fetal calf serum or carrier protein.

# Storage and Stability:

Stable for at least 6 months when stored at -20 °C. Avoid repeat freeze/thaws.

# Applications:

Inhibition of TNF-mediated apoptosis: Exerts inhibitory activity at concentrations higher than 1000 ng/ml. TNF-R2:Fc prefentially interacts with the membrane-bound form of TNF-α. Concentrations of rhTNF-R2 required to block killing may vary depending on cell type studied.

**Method:** Murine WEHI 164 cells (50,000 cells in 100  $\mu$ l RPMI medium containing 10% fetal calf serum) were plated in a 96 well plate. 100 pg/ml rhsTNF- $\alpha$  were incubated with the indicated concentrations of rhTNFR2:Fc for 30 minutes at RT. Then the mixture was added to the WEHI 164 target cells and incubated for at least 12 hr at 37°C. Concentrations of rhsTNF- $\alpha$  required to kill cells may vary depending on cell type studied. Concentrations of rhTNFR2:Fc required to block killing may vary depending on cell type studied.

Cell viability was determined using a MTTbased cell proliferation assay kit.

The optimal dilution for a specific application should be determined by the researcher.

#### Limitations:

For *in vitro* research use only. Not for use in diagnostics or in humans.

#### Warranty:

No warranties, expressed or implied, are made regarding the use of this product. **KAMIYA BIOMEDICAL COMPANY** is not liable for any damage, personal injury, or economic loss caused by this product.